Study on the Regulation of Chidamide on CD8+T Cells in T-cell Acute Lymphoblastic Leukemia.
10.19746/j.cnki.issn.1009-2137.2023.01.011
- Author:
Miao-Ming YAN
1
;
Zhao-Xuan LI
2
;
Chong CHEN
2
;
Wei ZHANG
1
;
Dao-Bin ZHOU
3
Author Information
1. Department of Hematology, Peking Union Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
2. Department of Immunology, Institute of Basic Medical Science CAMS, School of Basic Medicine PUMC, Beijing 100005, China.
3. Department of Hematology, Peking Union Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.E-mail: zhoudb@pumch.cn.
- Publication Type:Journal Article
- Keywords:
T-cell acute lymphoblastic leukemia;
chidamide;
lymphocyte
- MeSH:
Humans;
CD8-Positive T-Lymphocytes;
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;
Aminopyridines/pharmacology*;
Jurkat Cells;
RNA, Messenger;
Cell Line, Tumor;
Apoptosis;
Tumor Microenvironment
- From:
Journal of Experimental Hematology
2023;31(1):71-75
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the regulatory effect of chidamide on CD8+ T cells in T-cell acute lymphoblastic leukemia.
METHODS:The expression levels of CXCL9 and CXCL3 mRNA in Jurkat cells, lymphocytes treated with chidamide and lymphocytes co-cultured with chidamide-treated Jurkat cells were detected by fluorescence quantitative PCR. The proportion of CD8+ T cells in lymphocytes treated with chidamide and lymphocytes co-cultured with chidamide-treated Jurkat cells was determined by flow cytometry.
RESULTS:Chidamide upregulated CXCL9 mRNA expression in Jurkat cell line in a dose-dependent manner (r=0.950). The mRNA expression of CXCL9 in chidamide 5 μmol/L group was 164 times higher than that in control group. Chidamide upregulated CXCL9 mRNA expression in lymphocytes, but the up-regulated level was significantly lower than that in Jurkat cell line treated with the same concentration of chidamide. Co-culture with chidamide treated Jurkat cells upregulated the proportion of CD8+ T cells in lymphocytes.
CONCLUSION:In T-cell acute lymphoblastic leukemia, chidamide may increase the concentration of CXCL9 in the tumor microenvironment by up-regulating the expression of CXCL9 in tumor cells, leading to an increase in the number of CD8+ T cells.
